Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R J Motzer

Showing results (131-140 of 155) with videos related to

Pageof 16
Sort By:
European Journal of Cancer (Oxford, England : 1990)|January 3, 2012
Everolimus in metastatic renal cell carcinoma: Subgroup analysis of patients with 1 or 2 previous vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapies enrolled in the phase III RECORD-1 studyE Calvo, B Escudier, R J Motzer, et al.
European Journal of Cancer (Oxford, England : 1990)|April 5, 2016
Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptorV R Belum, B Benhuri, M A Postow, et al.
ESMO Open|April 27, 2023
Extended follow-up from JAVELIN Renal 101: subgroup analysis of avelumab plus axitinib versus sunitinib by the International Metastatic Renal Cell Carcinoma Database Consortium risk group in patients with advanced renal cell carcinomaJ B A G Haanen, J Larkin, T K Choueiri, et al.
British Journal of Cancer|January 18, 2014
Efficacy and safety of sunitinib in elderly patients with metastatic renal cell carcinomaT E Hutson, R M Bukowski, B I Rini, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 19, 2015
Phase II trial of second-line everolimus in patients with metastatic renal cell carcinoma (RECORD-4)R J Motzer, A Alyasova, D Ye, et al.
British Journal of Cancer|May 15, 2014
Axitinib versus sorafenib in advanced renal cell carcinoma: subanalyses by prior therapy from a randomised phase III trialB Escudier, M D Michaelson, R J Motzer, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 10, 2018
Adjuvant sunitinib in patients with high-risk renal cell carcinoma: safety, therapy management, and patient-reported outcomes in the S-TRAC trialM Staehler, R J Motzer, D J George, et al.
British Journal of Cancer|February 20, 2015
IL8 polymorphisms and overall survival in pazopanib- or sunitinib-treated patients with renal cell carcinomaC-F Xu, T Johnson, J Garcia-Donas, et al.
Kidney Cancer (Clifton, Va.)|October 19, 2018
Genomic Alterations and Outcomes with VEGF-Targeted Therapy in Patients with Clear Cell Renal Cell CarcinomaM I Carlo, B Manley, S Patil, et al.
European Journal of Cancer (Oxford, England : 1990)|May 11, 2019
Outcomes of patients with metastatic clear-cell renal cell carcinoma treated with second-line VEGFR-TKI after first-line immune checkpoint inhibitorsA Y Shah, R R Kotecha, E A Lemke, et al.
Pageof 16

Showing results (131-140 of 155) with videos related to

Sort By:
Pageof 16
European Journal of Cancer (Oxford, England : 1990)|January 3, 2012
Everolimus in metastatic renal cell carcinoma: Subgroup analysis of patients with 1 or 2 previous vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapies enrolled in the phase III RECORD-1 studyE Calvo, B Escudier, R J Motzer, et al.
European Journal of Cancer (Oxford, England : 1990)|April 5, 2016
Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptorV R Belum, B Benhuri, M A Postow, et al.
ESMO Open|April 27, 2023
Extended follow-up from JAVELIN Renal 101: subgroup analysis of avelumab plus axitinib versus sunitinib by the International Metastatic Renal Cell Carcinoma Database Consortium risk group in patients with advanced renal cell carcinomaJ B A G Haanen, J Larkin, T K Choueiri, et al.
British Journal of Cancer|January 18, 2014
Efficacy and safety of sunitinib in elderly patients with metastatic renal cell carcinomaT E Hutson, R M Bukowski, B I Rini, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 19, 2015
Phase II trial of second-line everolimus in patients with metastatic renal cell carcinoma (RECORD-4)R J Motzer, A Alyasova, D Ye, et al.
British Journal of Cancer|May 15, 2014
Axitinib versus sorafenib in advanced renal cell carcinoma: subanalyses by prior therapy from a randomised phase III trialB Escudier, M D Michaelson, R J Motzer, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 10, 2018
Adjuvant sunitinib in patients with high-risk renal cell carcinoma: safety, therapy management, and patient-reported outcomes in the S-TRAC trialM Staehler, R J Motzer, D J George, et al.
British Journal of Cancer|February 20, 2015
IL8 polymorphisms and overall survival in pazopanib- or sunitinib-treated patients with renal cell carcinomaC-F Xu, T Johnson, J Garcia-Donas, et al.
Kidney Cancer (Clifton, Va.)|October 19, 2018
Genomic Alterations and Outcomes with VEGF-Targeted Therapy in Patients with Clear Cell Renal Cell CarcinomaM I Carlo, B Manley, S Patil, et al.
European Journal of Cancer (Oxford, England : 1990)|May 11, 2019
Outcomes of patients with metastatic clear-cell renal cell carcinoma treated with second-line VEGFR-TKI after first-line immune checkpoint inhibitorsA Y Shah, R R Kotecha, E A Lemke, et al.
Pageof 16